Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement

Abstract

Rapid innovations in cardiovascular magnetic resonance (CMR) now permit the routine acquisition of quantitative measures of myocardial and blood T1 which are key tissue characteristics. These capabilities introduce a new frontier in cardiology, enabling the practitioner/investigator to quantify biologically important myocardial properties that otherwise can be difficult to ascertain clinically. CMR may be able to track biologically important changes in the myocardium by: a) native T1 that reflects myocardial disease involving the myocyte and interstitium without use of gadolinium based contrast agents (GBCA), or b) the extracellular volume fraction (ECV)–a direct GBCA-based measurement of the size of the extracellular space, reflecting interstitial disease. The latter technique attempts to dichotomize the myocardium into its cellular and interstitial components with estimates expressed as volume fractions. This document provides recommendations for clinical and research T1 and ECV measurement, based on published evidence when available and expert consensus when not. We address site preparation, scan type, scan planning and acquisition, quality control, visualisation and analysis, technical development. We also address controversies in the field. While ECV and native T1 mapping appear destined to affect clinical decision making, they lack multi-centre application and face significant challenges, which demand a community-wide approach among stakeholders. At present, ECV and native T1 mapping appear sufficiently robust for many diseases; yet more research is required before a large-scale application for clinical decision-making can be recommended.

Immune‐Mediated Myocarditis in Fabry Disease Cardiomyopathy

“…Immunosuppressive therapy (ie, a combination of prednisone with azathioprine17) or immunomodulating therapy (ie, immunoadsorption25) can be associated with ERT in those FDCM patients with advanced disease (groups 3 and 4) and CMR and/or histological evidence of myocarditis and refractory to the conventional management. The impact of immunosuppression can be relieved with improvement of major symptoms like chest pain, dyspnea, and cardiac arrhythmias and with the decrease or disappearance of serum antimyosin and antiheart antibodies.…”

Influence of fat on liver T1 measurements using modified Look–Locker inversion recovery (MOLLI) methods at 3T

“…THE MODIFIED LOOK–LOCKER INVERSION RECOVERY (MOLLI)1 T 1 mapping technique and variants of it have been gaining interest in cardiovascular magnetic resonance imaging (MRI)2 and in liver imaging 3. MOLLI is able to build a T 1 map within a breath‐hold.…”

Mechanisms for the Formation Myocardial Fibrosis in Norm and in Certain Cardiovascular Diseases, How to Diagnose It

“…Этот метод является наиболее пригод-ным для выявления инфаркта миокарда, где различия между нормальным и пострадавшим миокардом более отчетливы. Определение внеклеточного объема может обнаружить ранние изменения, связанные с фиброзом, которые не всегда обнаруживают при исследовании с замедленным выведением гадолиния [19][20][21].…”